Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels

ClinicalTrials.gov ID: NCT05161936

Public ClinicalTrials.gov record NCT05161936. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 1:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Lumasiran in Patients With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels

Study identification

NCT ID
NCT05161936
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Alnylam Pharmaceuticals
Industry
Enrollment
2 participants

Conditions and interventions

Interventions

  • Lumasiran Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 26, 2022
Primary completion
Oct 31, 2022
Completion
Oct 31, 2022
Last update posted
May 21, 2024

2022

United States locations

U.S. sites
17
U.S. states
13
U.S. cities
17
Facility City State ZIP Site status
Clinical Trial Site Birmingham Alabama 35233
Clinical Trial Site Northridge California 91324
Clinical Trial Site San Francisco California 94143
Clinical Trial Site Hialeah Florida 33016
Clinical Trial Site Acworth Georgia 30101
Clinical Trial Site Quincy Illinois 62301
Clinical Trial Site Carmel Indiana 46032
Clinical Trial Site Boston Massachusetts 02114
Clinical Trial Site Edina Minnesota 55435
Clinical Trial Site Rochester Minnesota 55905
Clinical Trial Site Las Vegas Nevada 89128
Clinical Trial Site Albany New York 12208
Clinical Trial Site Garden City New York 11530
Clinical Trial Site Greensboro North Carolina 27403
Clinical Trial Site North Charleston South Carolina 29405
Clinical Trial Site El Paso Texas 79902
Clinical Trial Site Houston Texas 77054

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05161936, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 21, 2024 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05161936 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →